work on an Integrated Cardiovascular Health (ICVH) initiative that integrates primary prevention, secondary prevention, and treatment for those at risk for cardiovascular disease and those with known coronary artery disease (CAD), diabetes, hypertension, and dyslipidemia. In addition to medication management, lifestyle risk factors such as weight management, tobacco cessation, primary prevention, and reduction of global cardiovascular risk are integrated into this initiative.
Over the last several years, the CMI-facilitated KP National Guideline Program (NGP) developed distinct national guidelines for CAD, diabetes, hypertension, and dyslipidemia. Over time, the scope of these individual guidelines increased. In certain cases, clinical recommendations were developed across these guidelines that overlapped, sometimes with conflicting advice.
LEARNING OBJECTIVES (TRAINING GOALS):
1. Identify and address opportunities to streamline clinical recommendations across related guidelines. 2. Avoid inconsistency in recommendations across related guidelines.
METHODS:
In 2009, to address these issues and better support the work of the ICVH initiative, the NGP began work to integrate its cardiovascular guidelines. We assembled a lead team made up of the clinical leads of each of the component guidelines that was charged with oversight and governance of the entire set of ICVH recommendations.
RESULTS:
The main product will be an Integrated CVD Risk Reduction Guideline. Clinical recommendations from the previous CAD, diabetes, hypertension, and dyslipidemia guidelines that relate to CVD risk reduction will be coordinated and pooled together. The individual guidelines will maintain some unique clinical recommendations.
DISCUSSION (CONCLUSION):
In the future, the complete CAD, diabetes, and hypertension guidelines will include both the pooled and the unique clinical recommendations. As the project progresses, individual recommendations will be updated as appropriate when new studies are published. We will present our progress to date on integrating these CVD guidelines. TARGET AUDIENCE(S): 1. Guideline developer 2. Developer of guideline-based products 3. Medical providers and executives Both sets of guidelines were developed with a similar methodology and found similar quality trials on which to base recommendations. Both methodologies relied on original synthesis of evidence and did not use systematic reviews in developing recommendations. In addition to a defined quality evidence process, ACOEM's methodology also includes a set of principles which guided panel interpretation of the evidence. These principles generally favor conservative versus invasive treatments in the absence of quality evidence for consensus recommendations. LEARNING OBJECTIVES (TRAINING GOALS): 1. Comparing same topic guidelines of similar methodologies. 2. Assessing the impact of insufficient evidence. METHODS: The ACOEM and APS evidence levels and recommendations were compared. RESULTS: ACOEM and APS generally agreed with evidence levels but had significant recommendation differences in low back interventional therapies, surgery, and interdisciplinary rehabilitation. APS had 16/30 (53%) interventions where insufficient evidence precluded a recommendation; of those, only botulinium injections had a corresponding "No Recommendation," the rest were "Not Recommended" by ACOEM. APS and ACOEM agreed on "Not Recommending" prolotherapy, intradiscal steroid injection, and facet joint steroid injection. Perhaps most interestingly, APS issued a weak recommendation for fusion surgery in patients with nonradicular pain and common degenerative changes where ACOEM concluded a "Not Recommended" for nonspecific low back pain.
S43-Low back interventions and opioid treatment guidelines: Comparison between ACOEM and APS

DISCUSSION (CONCLUSION):
These comparisons suggest that there is a significant potential for recommendation disagreement, especially when evidence is insufficient. Harmonization efforts should take into account value systems in addition to evidence methodologies. 
RESULTS:
The guidelines were developed in six months and will be released in March 2010. They contain seven recommendations and six good practice points that provide practical guidance for health-care providers. Implementation issues relate mainly to additional staff time required for setting up, maintaining and monitoring MgSO4 infusions. Individual hospitals will audit MgSO4 use with the intent for a national audit and linkage to cerebral palsy registers. The present guideline will be updated with any new data, such as the results of an individual patient data analysis, currently underway. DISCUSSION (CONCLUSION): These guidelines address a 'translational flashpoint' of new knowledge and demonstrate that development and implementation processes can be rapid, responsive, and agile without sacrificing scientific rigor and quality. Importantly, through helping to prevent cerebral palsy, these guidelines should lessen the devastating consequences of preterm birth. TARGET AUDIENCE(S): 1. Clinical researcher 2. Evidence synthesizer, developer of systematic reviews or meta-analyses 3. Guideline developer 4. Guideline implementer 5. Quality improvement manager/facilitator 6. Health care policy analyst/policymaker 7. Medical providers and executives 8. Consumers' and patients' representatives 9. Nurses
